The company will permit six generic drugmakers to make and sell lenacapavir in 120 countries that have high incidence of the disease, but limited resources.
October 1st, 2024 - AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, is announcing ...
The latest investment in the Lebanon site comes after an announcement in May of $5.3 billion earmarked to build production capacity for Lilly’s obesity and diabetes drugs. All told, the company said ...
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback